Phase II trial of @entity1138 plus @entity1487 in the treatment of XXXX .

@entity43 @entity1 @entity137 @entity66 @entity882 @entity1138 @entity900 @entity1431 @entity236 @entity1487
Following @entity900 combination chemotherapy for advanced @entity43 , response to subsequent treatments has proved relatively poor. @entity1138 and @entity1487 ( @entity1487 ) have both been reported to have useful activity as single agents in @entity1 with @entity43 . We have carried out a phase II trial of a combination of these two agents in 25 @entity1 who had previously received a median of two chemotherapy regimens (range, one to five regimens). @entity1 received @entity1138 , 10 mg/m2 intravenously (IV) on day 1 every 6 weeks, and @entity1487 , 500 mg/m2 IV daily on days 1 to 3 every 3 weeks. Four @entity1 experienced a complete response and six @entity1 a partial response, for an overall objective response rate of 40%. The median duration of complete and partial responses was 8 and 4 months, respectively. The median duration of survival for all 25 @entity1 was 10.5 months (range, 2.5 to 49+ months). The most prevalent @entity137 was @entity236 . @entity1431 occurred in 68% of the @entity1 , and 36% experienced @entity882 . Severe or life-threatening @entity236 was observed in 36% of the @entity1 and required dose reduction or drug discontinuance in 28% and 24%, respectively. We conclude that @entity1138 plus @entity1487 combination therapy appears to be extremely active in @entity1 with @entity66 . Confirmatory trials are indicated.
